Extended Data Fig. 5: CD8 T cell responses in Cd27-/-, Tnfrsf9-/-, and Cd27-/- Tnfrsf9-/-mice.
From: Mechanisms of CD40-dependent cDC1 licensing beyond costimulation
a, Schematic diagram showing generation of Tnfrsf9-/-mice. CRISPR/Cas9 and sgRNAs were used to target the first coding exon, exon II, resulting in a Tnfrsf9 null gene via indel. b, WT, Cd27-/-, and Tnfrsf9-/- mice were injected with 106 1969 cells, and spleens were stained for the presence of mGpd2 tetramer+ CD8 T cells on day 10. Data represent pooled biologically independent samples from five independent experiments (n = 6 for naive, n = 9 for WT, n = 8 for Cd27-/-, n = 5 for Tnfrsf9-/- mice). Data are represented as mean values +/− s.d. **P = 0.0023; ns = not significant. c, CD127, CD44, and CD62L geometric mean MFI of SPLENIC SIINFEKL-Kb-tetramer+ CD8 T cells on d10 of 1956-mOVA in WT, Cd27-/-, Tnfrsf9-/-, and Cd27-/-Tnfrsf9-/- mice. Data represent pooled biologically independent samples from four independent experiments (n = 12 for WT, n = 10 for Cd27-/-, n = 6 for Tnfrsf9-/- mice, and n = 8 for Cd27-/-Tnfrsf9-/- mice). Data are represented as mean values +/− s.d. **P = 0.0094, ***P = 0.0004, ****P = < 0.0001, ns = not significant. d, Individual tumor curves of WT (Cd27-/-) and Cd27-/- mice during primary and secondary implantation with 1956 progressor tumor. b,c: Brown–Forsythe and Welch ANOVA with Dunnett’s T3 multiple comparisons test.
